Skip to main content

Clinical trial Mountaineer-03

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer(SGNTUC-029 - Mountaineer-03)

Cancers
Organ Multiple
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Seagen
EudraCT Identifier 2021-002672-40
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05253651
Last update